Profiel
Emmanuelle Charpentier is the founder of CRISPR Therapeutics AG, founded in 2013, and ERS Genomics Ltd., founded in 2014.
At ERS Genomics Ltd., she holds the title of Scientific Advisor, which she has held since 2014.
Actieve functies van Emmanuelle Charpentier
| Bedrijven | Functie | Begin |
|---|---|---|
ERS Genomics Ltd.
 ERS Genomics Ltd. BiotechnologyHealth Technology ERS Genomic Ltd. engages in the development of biotechnology. It was formed to provide broad access to the foundational CRISPR-Cas9, a new genome editing technology, which offers speed, efficiency, and cost over earlier genome editing methods. The company was founded by Emmanuelle Charpentier and Shaun Foy in 2014 and is headquartered in Dublin, Ireland. | Oprichter | 01-01-2014 |
Eerdere bekende functies van Emmanuelle Charpentier
| Bedrijven | Functie | Einde |
|---|---|---|
| CRISPR THERAPEUTICS AG | Oprichter | - |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| CRISPR THERAPEUTICS AG | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
ERS Genomics Ltd.
ERS Genomics Ltd. BiotechnologyHealth Technology ERS Genomic Ltd. engages in the development of biotechnology. It was formed to provide broad access to the foundational CRISPR-Cas9, a new genome editing technology, which offers speed, efficiency, and cost over earlier genome editing methods. The company was founded by Emmanuelle Charpentier and Shaun Foy in 2014 and is headquartered in Dublin, Ireland. | Health Technology |
